Figure 4

Identification of putative SPD transporters in primary human melanocytes. (a) RNA-sequencing analysis of 1 µg of total RNA of primary melanocytes representing the expression levels of solute carrier (SLC) family transporters. (b) mRNA expression levels of primary melanocytes after treatment with 1 μM of SPD for 10 days. The data represent the results of three independent experiments. CTL: control, NS: non-significant, *P < 0.05, **P < 0.01, ***P < 0.005. (c) Schematic representation of the effects of SPD treatment in the improvement of the stabilities of TRP-1 and TRP-2 through the increase of the cellular polyamine pool.